Prevalence of a particularly dangerous form of methicillin resistant Staphylococcus aureus (MRSA) jumped three-fold in just two years, in hospitals in the United Kingdom, according to a paper in the October 2012 issue of the Journal of Clinical Microbiology.
This particular pathogen emerged in the U.S. in 1998, and "is endemic within many US hospitals," an observation which led to the current study being conducted, says coauthor Gopal Rao of Northwick Park Hospital, Harrow, Middlesex, UK.
The MRSA in question contains a toxin called Panton-Valentine leukocidin (PVL), which destroys leukocytes (a type of white blood cell), kills skin and mucus membranes, and confers increased virulence. In some cases, they cause invasive disease, most notably necrotizing hemorrhagic pneumonia, which has a high mortality rate.
The United Kingdom's Health Protection Agency first reported that PVL-methicillin resistant S. aureus (PVL-MRSA) was an emerging disease in UK in 2005. While most of the MRSA gets transmitted from one person to another within the hospital, most patients infected with MRSA containing the PVL toxin genes acquired it outside of the hospital ("community acquired" MRSA). The Department of Health in UK mandated screening for MRSA in 2008.
Rao and collaborators set out to find out how many patients entering the hospital carried community-acquired MRSA, especially that containing the dangerous PVL genes. During the study period, cases of community-acquired PVL-MRSA jumped threefold, from 0.07 percent to 0.22 percent, while the numbers of patients with hospital-acquired MRSA dropped from 4.6 percent to 2.8 percent. One particular clone of PVL-MRSA, which also carries resistance to clindamycin and tetracycline is particularly worrisome, the researchers note.
Most of the patients carrying PVL-containing strains are males. The study included 56,000 patients.
Reference: Pantelides NM, et al. Preadmission screening of adults highlights previously unrecognized carriage of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus in London: a cause for concern? J. Clin. Microbiol. 50:3168-3171. 2012.
Â
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.